Newly developed retatrutide, a combined-action medication targeting equally GLP-1 and GIP receptors, is creating considerable buzz within the healthcare community. Early clinical research have shown substantial reductions in body mass and improvements in metabolic markers for patients with excess weight . Scientists believe this novel approach cou